Headlines

CBDC Stream engages AlbR Capital for LSE, SEHK listings

FOR IMMEDIATE RELEASE (London, November 27, 2025) – CBDC Stream and AlbR Capital Ltd. (“AlbR”) announced today that AlbR has been mandated to advise, arrange, and help complete a Main Board listing of CBDC Stream on the London Stock Exchange (“LSE”) in the first quarter of

EU watchdog calls for 'better balance' in law making

European Ombudswoman Teresa Anjinho (pictured) has found a number of “procedural shortcomings” in how the European Commission prepared several legislative proposals that it considered urgent. Taken together the shortcomings amounted to maladministration, says the official. The

Asia’s faith in the ‘Powell put’ may be misplaced

TOKYO – Asian markets have an ace in the hole as a tumultuous 2025 comes to a close: Jerome Powell. On Thursday, the region’s stock bourses rose again, extending the week’s global rally, amid widespread expectations that US Federal Reserve Chair Powell and his fellow board

Gratitude and empathy

Empathy is difficult. I’m not you, I can’t imagine the path you’ve traveled, the stories you tell yourself and the pressures you’re under. But real gratitude requires empathy. Everyone is under the circumstances. Everyone does the best they think they can with the options they

RNA in action: Filming ribozyme self-assembly

RNA is a central biological macromolecule, now widely harnessed in medicine and nanotechnology. Like proteins, RNA function often depends on its precise three-dimensional structure. A recent study published in Nature Communications by Marcia group, has captured, for the first

Drones: An ally in the sky to help save elephants

They say an elephant never forgets—and it turns out they can learn to adapt to drones. Once seen as a source of alarm, drones are now proving to be surprisingly elephant-friendly and a valuable research tool. Previously, the use of drones in elephant conservation has mostly

Brazil approves locally produced dengue vaccine

Brazil's National Health Surveillance Agency (Anvisa) has approved the final administrative step before the formal registration of the single-dose dengue vaccine developed by the São Paulo-based Butantan Institute for people aged 12 to 59, which protects against all four virus